During 2019, The Center for Biosimilars® provided interviews and discussions with key opinion leaders on our podcast to discuss various issues affecting biosimilars. From patent issues to the arrival of oncology biosimilars, here is a look at our top 5 podcast episodes from 2019.
During 2019, The Center for Biosimilars® provided interviews and discussions with key opinion leaders on our podcast, “Not So Different,” to discuss various issues affecting biosimilars. From patent issues to the arrival of oncology biosimilars, here is a look at our top 5 podcast episodes from 2019.
5. "What's Holding Back Biosimilars? It May Not Be Pay-for-Delay Deals
Pay-for-delay issues were big news on Capitol Hill, and some experts questioned whether these kinds of settlements are really at the heart of delayed biosimilar competition. Might there be alternative ways to think about, and fix, the problem? On this episode, we spoke with 2 such experts, Imron Aly, JD, and Joel Wallace, JD. Both are partners at Schiff Hardin LLP and have extensive experience with Hatch-Waxman and biosimilars intellectual property issues.
4. A Look Ahead to Biosimilar Insulin
2020 will bring the transition of insulin to regulation as biologics. On this episode, we spoke with one of the experts who testified at a FDA public hearing about biosimilar insulins, which happened amid growing concern about the skyrocketing cost of insulin in the United States. Steven Lucio, PharmD, BCPS, associate vice president of clinical solutions and pharmacy program development at Vizient, shared his thoughts with us on biosimilar insulins, interchangeability, biosimilar suffixes, and what milestones lie ahead as the United States approaches the transition.
3. Is It Time to Give Up on Biosimilars?
It’s no secret that the biosimilars market in the United States has been off to a sluggish start. In fact, former FDA Commissioner Scott Gottlieb, MD, went so far as to call the market anemic. On this episode, we talked with Mark Trusheim, MS, one of the authors of a proposal to do away with the US biosimilars market altogether. Trusheim, a biopharmaceuticals consultant, is also the strategic director of the NEWDIGS program at the Massachusetts Institute of Technology (MIT) Center for Biomedical innovation and a visiting scientist in applied economics at MIT’s Sloan School of Management.
2. Where Are We Headed With Oncology Biosimilars? Vizient Weighs In
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs. We spoke once again with Vizient’s Steven Lucio, PharmD, BCPS, on how oncology biosimilars are poised to make an impact.
1. What Have We Learned So Far About US Oncology Biosimilars?
Among the biggest biosimilars news of this year was the launch of the first 2 anticancer biosimilars. On this episode, we talked with an expert who's sharing her insight into these developments in the oncology space. Christina Corridon, MPH, MBA, is a principal at the professional services firm ZS Associates, where she is a leader in ZS' oncology practice and leads their biosimilars vertical. She joined us to talk about the state of play in the US biosimilars market, what we can learn from ongoing experience, and how sustainable the US market for biosimilars may be today.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.